The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Feature|Articles|September 2, 2023
- Pharmaceutical Technology, September 2023
- Volume 47
- Issue 9
- Pages: 26
Size Exclusion Chromatography Columns
Author(s)Pharmaceutical Technology Editors
Waters Corporation’s XBridge Premier GTx BEH size exclusion chromatography (SEC) columns are designed to improve analysis while lowering the cost of gene therapies.
Advertisement
Waters Corporation’s XBridge Premier GTx BEH size exclusion chromatography (SEC) columns are designed to improve analysis while lowering the cost of gene therapies, specifically for adeno-associated viral (AAV) vectors. SEC is a technique used for aggregate and fragment analysis in the research, development, and manufacturing of biotherapeutic proteins, such as insulin and monoclonal antibodies.
The columns aim to reduce the cost of gene therapies by using three to 10x less sample, generating faster results and offering more drug substance information. Additionally, a new multi-attribute quantification method is intended to double analytical speed, quadruple sensitivity, and increases resolution of target analytes by up to 50%.
The Xbridge columns are designed to take robust physicochemical characterization and quantitative measurements. Aiming to double the speed of measuring the potency and safety of AAVs, the SEC columns are intended for process development, formulation studies, regulatory filing support, ongoing process monitoring, and quality control.
Articles in this issue
about 3 years ago
In Equal Measures: The Importance of Excipient Qualityabout 3 years ago
Harnessing the Power of Oncolytic Virusesabout 3 years ago
Formulating with Coprocessed Excipients: Current Trendsabout 3 years ago
Improving Manufacturing Flexibility with Modulesabout 3 years ago
Preserving Process Integrity: The Importance of Equipment Cleaningabout 3 years ago
Outsourcing Formulation Services for Biologicsabout 3 years ago
Accelerating Clinical Trials in the EUabout 3 years ago
Booster Shot for PharmaAdvertisement
Related to this article
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
Advertisement
Advertisement